

Regioselective glycosylation of 4,6-*O*-benzylidenated glucopyranosides

Ying Zeng, Fanzuo Kong*

Research Center for Eco-Environmental Sciences, Academia Sinica, Chinese Academy of Sciences, P.O. Box 2871, Beijing 100085, China

Received 22 November 2002; accepted 13 January 2003

Abstract

Regioselective glycosylation with allyl 4,6-*O*-benzylidene- α,β -D-glucopyranoside or methyl 4,6-*O*-benzylidene- α,β -D-glucopyranoside as the acceptor was investigated. It was found that the regioselectivity depends upon donor size and anomeric configuration of the acceptor, i.e., with a monosaccharide donor and an α -form acceptor, the (1 \rightarrow 3)-linked product was obtained predominantly or exclusively, while with disaccharide or trisaccharide donors and either an α or β form acceptor, the (1 \rightarrow 2)-linked oligosaccharides were the only products. © 2003 Elsevier Science Ltd. All rights reserved.

Keywords: Glucose oligosaccharides; Trichloroacetimidates; Regioselective glycosylation

1. Introduction

Regioselective coupling is an effective and concise method for the synthesis of oligosaccharides as it can simplify the synthetic route substantially and avoid a tedious protection–deprotection procedure. Just like stereoselective formation of the glycosidic linkage, the results of regioselective coupling are influenced by many factors.¹ Recently, a series of work on regioselective coupling has been carried out in our group, resulting in a variety of branched mannose, rhamnose, and glucose oligosaccharides.²

β -(1 \rightarrow 3)-Linked glucans occur in some biologically important natural products, such as schizophyllan, scleroglucan and lentinan with antitumor activity,³ and the β -(1 \rightarrow 2)-glucosyl linkage occurs in the capsular polysaccharide of *Streptococcus pneumoniae* type 37^{4a} and in the exopolysaccharide of *Pediococcus domnosus*.^{4b} 4,6-*O*-Benzylidenated glucopyranosides are good acceptors since their 3-*O*- or 2-*O*-selective coupling with appropriate donors can afford (1 \rightarrow 3)- or (1 \rightarrow 2)-linked oligosaccharides, based on which useful fragments of natural polysaccharides can be synthesized. However,

there is a very subtle distinction between the 2-OH and the 3-OH of the acceptors, and the activity of the 3-OH is little bit greater than that of the 2-OH when fully benzylated glucosyl trichloroacetimidate was used as the donor.⁵ We present herein 3-*O*- or 2-*O*-regioselective glycosylation of 4,6-*O*-benzylidenated glucosides with fully benzoylated glucosyl trichloroacetimidates as donors.

2. Results and discussion

As shown in Scheme 1, glycosylation of methyl 4,6-*O*-benzylidene- α -D-glucopyranoside (**2**) with 2,3,4,6-tetra-*O*-benzoyl- α -D-glucopyranosyl trichloroacetimidate (**1**) afforded a mixture of β -(1 \rightarrow 3)-linked disaccharide **3** (53%) and β -(1 \rightarrow 2)-linked disaccharide **4** (24%), and no α -linked product was detected. Compounds **3** and **4** were isolated and characterized by their acetylation to give the corresponding 2-acetate and 3-acetate, respectively. The former showed H-2 at δ 4.77 ppm with $J_{1,2} = 4.0$, $J_{2,3} = 9.6$ Hz, and the latter showed H-3 at δ 5.46 ppm with $J_{2,3} = J_{3,4} = 9.6$ Hz in their ¹H NMR spectra. It was interesting to find that coupling of **1** with the allyl glucoside **5** instead of **2**, gave exclusive β -(1 \rightarrow 3)-linked disaccharide **6** (75%), disclosing that allyl, instead of methyl, as the aglycon moiety of the acceptor led to 3-*O*-glycosylation. It was also found


* Corresponding author. Tel.: +86-10-62936613; fax: +86-10-62923563

E-mail address: fzkong@mail.rcees.ac.cn (F. Kong).


that condensation of **5** with the donor, 2,3-di-*O*-acetyl-4,6-*O*-benzylidene- α -D-glucopyranosyl trichloroacetimidate (**7**), yielded solely the β -(1 \rightarrow 3)-linked disaccharide **8** (81%). To examine the effect of anomeric configuration in the acceptor, methyl 4,6-*O*-benzylidene- β -D-glucopyranoside (**9**) and allyl 4,6-*O*-benzylidene- β -D-glucopyranoside (**12**) were used as the acceptors for coupling with **1**. Again, the regioselectivity was established by acetylation. In the ^1H NMR spectra of the acetylated compounds, H-2 was found by irradiation of H-1. For the 3-*O*-glycosylation, H-2 appeared at $\delta \sim 5.0$ ppm, whereas for the 2-*O*-glycosylation, H-2 appeared at δ 3.58–3.83 ppm. It was found that the regioselectivity was changed substantially along with the configuration alteration, i.e., β -glucoside **9** inversely gave (1 \rightarrow 2)-linked **11** (63%) as the major product and

(1 \rightarrow 3)-linked **10** (20%) as the minor one. Meanwhile, β -glucoside **12** afforded (1 \rightarrow 2)-linked **14** and (1 \rightarrow 3)-linked **13** in almost equivalent amounts. However, glycosylation of the acceptor **2** or **5** or their β anomer **9** or **12** with β -(1 \rightarrow 3)-linked disaccharide **17** or β -(1 \rightarrow 6)-linked disaccharide **15** or 3,6-branched trisaccharide **22**, always furnished (1 \rightarrow 2)-linked oligosaccharides, indicating that large size donors intended to give (1 \rightarrow 2)-regioselectivity (Scheme 2).

Vasella's group⁵ explored the regioselectivity–structure relationship. They found that the glycosylation regioselectivity depends upon the relative strength of the intramolecular H-bonds of the acceptors when the donors were monosaccharides. Fraser-Reid and co-workers⁶ found that a 2-*O*-benzoyl group in the donor gave more 2-linked product compared to the 2-*O*-ben-



Scheme 1.



Scheme 2.

zyl group when the acceptors were methyl 4,6-*O*-benzylidene- α,β -D-glucopyranosides. In our research, di- or trisaccharide donors exclusively gave 2-*O*-glycosylation products, and the β -form of the acceptor tended to give 2-*O*-glycosylation. We hypothesized that the large-size donors had a serious repulsion with the benzylidene group of the acceptor, making 3-*O* less reactive than 2-*O*, and the β -form of the acceptor had less steric hindrance between the donor and aglycon, leading to more of the (1 \rightarrow 2)-linkage.

In summary, the regioselectivity of glycosylation of a 4,6-*O*-benzylidene glucopyranoside depends upon donor size and anomeric configuration of acceptor.

With a monosaccharide donor and an α -form acceptor, (1 \rightarrow 3)-linked product was obtained predominantly or exclusively, while with di- or trisaccharide as the donors, (1 \rightarrow 2)-linked oligosaccharides were the only products.

3. Experimental

3.1. General methods

Optical rotations were determined at 25 °C with a Perkin–Elmer Model 241-Mc automatic polarimeter.

^1H , ^{13}C NMR were recorded with Bruker ARX 400 spectrometers (400 MHz for ^1H , 100 MHz for ^{13}C) at 25 °C for solutions in CDCl_3 or D_2O as indicated. Thin-layer chromatography (TLC) was performed on silica gel HF₂₅₄ with detection by charring with 30% (v/v) H_2SO_4 in MeOH or in some cases by a UV lamp. Column chromatography was conducted by elution of a column (8 × 240, 18 × 300, 35 × 400 mm) of silica gel (100–200 mesh) with EtOAc–petroleum ether (bp 60–90 °C) as the eluent. Solutions were concentrated at < 60 °C under reduced pressure.

3.2. Methyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 → 3)-4,6-*O*-benzylidene- α -D-glucopyranoside (3)

Compounds **2** (150 mg, 0.20 mmol) and **1** (60 mg, 0.21 mmol) were dried together under high vacuum for 2 h, then dissolved in anhyd CH_2Cl_2 (5 mL). TMSOTf (8 μL) was added dropwise at –20 °C with N_2 protection. The reaction mixture was stirred for 3 h, during which time the temperature was gradually raised to ambient temperature. Then the mixture was neutralized with Et_3N . Concentration of the reaction mixture, followed by purification on a silica gel column with 2:1 petroleum ether–EtOAc as the eluent, gave two disaccharides with R_f 0.45 and 0.60 on TLC (2:1 petroleum ether–EtOAc), respectively. The disaccharide with R_f 0.45 was acetylated in pyridine (2 mL) with Ac_2O (0.5 mL) for 3 h, then concentrated to dryness. The residue was purified by flash chromatography (3:1 petroleum ether–EtOAc) to give the 2-acetate of **3** (95 mg, 53% for two steps) as a syrup: $[\alpha]_{\text{D}} + 17.0^\circ$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.93–7.25 (m, 25 H, PhH), 5.85 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.65 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.600 (s, 1 H, PhCH), 5.50 (dd, 1 H, $J_{1',2'} = 8.0$, $J_{2',3'} = 9.6$ Hz, H-2'), 5.07 (d, 1 H, $J_{1',2'} = 8.0$ Hz, H-1'), 4.85 (d, 1 H, $J_{1,2} = 4.0$ Hz, H-1), 4.77 (dd, 1 H, $J_{2,3} = 9.6$, $J_{1,2} = 4.0$ Hz, H-2), 4.47 (dd, 1 H, $J_{6'a,6'b} = 12.0$, $J_{5',6'a} = 3.6$ Hz, H-6'a), 4.30–4.24 (m, 3 H), 3.91–3.73 (m, 4 H), 3.32 (s, 3 H, CH_3O), 1.77 (s, 3 H, CH_3CO). Anal. Calcd for $\text{C}_{50}\text{H}_{46}\text{O}_{16}$: C, 66.51; H, 5.14. Found: C, 66.79; H, 5.01.

3.3. Methyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 → 2)-4,6-*O*-benzylidene- α -D-glucopyranoside (4)

The disaccharide with R_f 0.60 in Section 3.2, above, was acetylated with Ac_2O in pyridine to give the 3-acetate of **4** (45 mg, 24% for two steps): $[\alpha]_{\text{D}} + 13.2^\circ$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 8.03–7.25 (m, 25 H, PhH), 5.93 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.69 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.55 (dd, 1 H, $J_{1',2'} = 7.8$, $J_{2',3'} = 9.6$ Hz, H-2'), 5.46 (dd, 1 H, $J_{3,4} = J_{2,3} = 9.6$ Hz, H-3), 5.41 (s, 1 H, PhCH), 5.01 (d, 1 H, $J_{1,2} = 3.2$ Hz, H-1), 4.99 (d, 1 H, $J_{1',2'} = 7.8$ Hz, H-1'), 4.77–3.85 (m, 5 H), 3.74 (dd, $J_{1,2} = 3.2$, $J_{2,3} = 9.6$ Hz, H-2),

3.71–3.46 (m, 2 H), 3.37 (s, 3 H, CH_3O), 1.70 (s, CH_3CO). Anal. Calcd for $\text{C}_{50}\text{H}_{46}\text{O}_{16}$: C, 66.51; H, 5.14. Found: C, 66.27; H, 5.22.

3.4. Allyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 → 3)-4,6-*O*-benzylidene- α -D-glucopyranoside (6)

The 2-acetate of **6** (138 mg, 75% for two steps) was obtained as a syrup by coupling of **1** (150 mg, 0.20 mmol) with **5** (62 mg, 0.20 mmol), followed by acetylation under the same conditions as described for the preparation of the 2-acetate of **3**: $[\alpha]_{\text{D}} + 15.3^\circ$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.95–7.26 (m, 25 H, PhH), 5.82 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.81–5.72 (m, 1 H, $-\text{CH}=\text{}$), 5.66 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.60 (s, 1 H, PhCH), 5.50 (dd, 1 H, $J_{1',2'} = 8.0$, $J_{2',3'} = 9.6$ Hz, H-2'), 5.22–5.13 (m, 2 H, $=\text{CH}_2$), 5.09 (d, 1 H, $J_{1',2'} = 8.0$ Hz, H-1'), 5.00 (d, 1 H, $J_{1,2} = 3.6$ Hz, H-1), 4.76 (dd, 1 H, $J_{1,2} = 4.0$, $J_{2,3} = 9.6$ Hz, H-2), 4.47 (dd, 1 H, $J_{6'a,6'b} = 12.4$, $J_{5',6'a} = 3.2$ Hz, H-6'a), 4.34–4.23 (m, 3 H), 4.10–3.89 (m, 4 H), 3.79–3.74 (m, 2 H), 1.74 (s, 3 H, CH_3CO). Anal. Calcd for $\text{C}_{52}\text{H}_{48}\text{O}_{16}$: C, 67.27; H, 5.21. Found: C, 67.43; H, 5.19.

3.5. Allyl 2,3-di-*O*-acetyl-4,6-*O*-benzylidene- β -D-glucopyranosyl-(1 → 3)-4,6-*O*-benzylidene- α -D-glucopyranoside (8)

The 2-acetate of **8** (110 mg, 81% for two steps) was obtained as a syrup by coupling of **7** (100 mg, 0.20 mmol) with **5** (62 mg, 0.20 mmol), followed by acetylation under the same conditions as described for the preparation of the 2-acetate of **3**: $[\alpha]_{\text{D}} + 15.3^\circ$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.51–7.34 (m, 10 H, PhH), 5.91–5.82 (m, 1 H, $-\text{CH}=\text{}$), 5.57 (s, 1 H, PhCH), 5.34 (s, 1 H, PhCH), 5.33–5.21 (m, 2 H, $=\text{CH}_2$), 5.21 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.05 (d, 1 H, $J_{1,2} = 4.0$ Hz, H-1), 5.01 (dd, 1 H, $J_{1',2'} = 7.8$, $J_{2',3'} = 9.6$ Hz, H-2'), 4.88 (d, 1 H, $J_{1',2'} = 7.8$ Hz, H-1'), 4.86 (dd, $J_{1,2} = 4.0$, $J_{2,3} = 9.6$ Hz, H-2), 4.32–4.16 (m, 4 H), 4.02–3.89 (m, 2 H), 3.79–3.63 (m, 4 H), 3.49–3.42 (m, 1 H), 2.16 (s, 3 H, CH_3CO), 2.04 (s, 6 H, $2\text{CH}_3\text{CO}$). Anal. Calcd for $\text{C}_{35}\text{H}_{40}\text{O}_{14}$: C, 61.40; H, 5.89. Found: C, 61.31; H, 5.97.

3.6. Methyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 → 3)-4,6-*O*-benzylidene- β -D-glucopyranoside (10)

The 2-acetate of **10** (115 mg, 63% for two steps) was obtained as a syrup by coupling of **1** (150 mg, 0.20 mmol) with **9** (60 mg, 0.21 mmol), followed by silica gel separation and acetylation under the same conditions as described for the preparation of the 2-acetate of **3**: $[\alpha]_{\text{D}} + 13.5^\circ$ (c 1.0, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.92–7.26 (m, 25 H, PhH), 5.79 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.63 (dd, 1 H, $J_{3',4'} = J_{2',3'}$

9.6 Hz, H-3'), 5.58 (s, 1 H, PhCH), 5.46 (dd, 1 H, $J_{1,2'}$ 8.0, $J_{2,3'}$ 9.6 Hz, H-2'), 5.05 (d, 1 H, $J_{1,2'}$ 8.0 Hz, H-1'), 4.98 (dd, 1 H, $J_{1,2}$ 8.0, $J_{2,3}$ 8.8 Hz, H-2), 4.45–4.33 (m, 2 H), 4.30 (d, 1 H, $J_{1,2}$ 8.0 Hz, H-1), 4.24–4.20 (m, 1 H), 4.02–3.97 (m, 1 H), 3.84–3.77 (m, 3 H), 3.47–3.42 (m, 1 H), 3.37 (s, 3 H, CH₃O), 1.73 (s, 3 H, CH₃CO). Anal. Calcd for C₅₀H₄₆O₁₆: C, 66.51; H, 5.14. Found: C, 66.32; H, 5.17.

3.7. Methyl 2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl-(1 → 2)-4,6-*O*-benzylidene-β-D-glucopyranoside (11)

The 3-acetate of **11** (35 mg, 20%, two steps) was prepared as a syrup under the same conditions as described for the preparation of the 3-acetate of **4**: $[\alpha]_D + 16.8^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.92–7.24 (m, 25 H, PhH), 5.85 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.72 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.48 (dd, 1 H, $J_{1',2'}$ 8.0, $J_{2',3'}$ 9.6 Hz, H-2'), 5.37 (s, 1 H, PhCH), 5.25 (d, 1 H, $J_{1',2'}$ 8.0 Hz, H-1'), 5.19 (dd, 1 H, $J_{3,4} = J_{2,3} = 9.6$ Hz, H-3), 4.67 (dd, 1 H, $J_{6'a,6'b}$ 12.4, $J_{5',6'a}$ 3.2 Hz, H-6'a), 4.57 (d, 1 H, $J_{1,2}$ 8.0 Hz, H-1), 4.48 (dd, 1 H, $J_{6'a,6'b}$ 12.4, $J_{5',6'b}$ 3.2 Hz, H-6'b), 4.28 (dd, 1 H, $J_{6a,6b}$ 12.0, $J_{5,6a}$ 3.2 Hz, H-6a), 4.18 (dd, 1 H, $J_{6a,6b}$ 12.0, $J_{5,6b}$ 3.2 Hz, H-6b), 3.76 (dd, 1 H, $J_{1,2}$ 8.0, $J_{2,3}$ 9.6 Hz, H-2), 3.69–3.55 (m, 2 H), 3.51 (s, 3 H, CH₃O), 3.79–3.45 (m, 1 H), 1.73 (s, 3 H, CH₃CO). Anal. Calcd for C₅₀H₄₆O₁₆: C, 66.51; H, 5.14. Found: C, 66.61; H, 5.20.

3.8. Allyl 2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl-(1 → 3)-4,6-*O*-benzylidene-β-D-glucopyranoside (13)

The 2-acetate of **13** (77 mg, 41% for two steps) was obtained as a syrup by coupling of **1** (150 mg, 0.20 mmol) with **12** (62 mg, 0.20 mmol), followed by silica gel separation and acetylation under the same conditions as described for the preparation of the 2-acetate of **3**: $[\alpha]_D + 8.0^\circ$ (*c* 2.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.95–7.25 (m, 25 H, PhH), 5.81 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.76–5.70 (m, 1 H, –CH=), 5.64 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.59 (s, 1 H, PhCH), 5.48 (dd, 1 H, $J_{1',2'}$ 8.0, $J_{2',3'}$ 9.6 Hz, H-2'), 5.20–5.09 (m, 2 H, =CH₂), 5.05 (d, 1 H, $J_{1',2'}$ 8.0 Hz, H-1'), 5.03 (dd, 1 H, $J_{1,2}$ 8.0, $J_{2,3}$ 8.8 Hz, H-2), 4.47–4.43 (m, 1 H), 4.43 (d, 1 H, $J_{1,2}$ 8.0 Hz, H-1), 4.33 (m, 1 H), 4.26–4.22 (m, 2 H), 4.04–3.95 (m, 2 H), 3.91–3.78 (m, 3 H), 3.47–3.39 (m, 1 H), 1.73 (s, 3 H, CH₃CO). Anal. Calcd for C₅₂H₄₈O₁₆: C, 67.27; H, 5.21. Found: C, 66.97; H, 5.20.

3.9. Allyl 2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl-(1 → 2)-4,6-*O*-benzylidene-β-D-glucopyranoside (14)

The 3-acetate of **14** (75 mg, 41%, two steps) was prepared as a syrup under the same conditions as

described for the preparation of the 3-acetate of **4**: $[\alpha]_D + 6.5^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.04–7.25 (m, 25 H, PhH), 5.95–5.84 (m, 1 H, CH=), 5.86 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.75 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 5.49 (dd, 1 H, $J_{1',2'}$ 8.0, $J_{2',3'}$ 9.6 Hz, H-2'), 5.38 (s, 1 H, PhCH), 5.36–5.31 (m, 1 H, =CH_{2a}), 5.28 (d, 1 H, $J_{1',2'}$ 8.0 Hz, H-1'), 5.21 (dd, 1 H, $J_{3,4} = J_{2,3} = 9.2$ Hz, H-3), 5.19–5.15 (m, 1 H, =CH_{2b}), 4.72 (d, 1 H, $J_{1,2}$ 7.8 Hz, H-1), 4.64 (dd, 1 H, $J_{6'a,6'b}$ 12.4, $J_{5',6'a}$ 3.2 Hz, H-6'a), 4.47–4.13 (m, 5 H), 3.83 (dd, 1 H, $J_{1,2}$ 8.0, $J_{2,3}$ 9.2 Hz, H-2), 3.68–3.46 (m, 3 H), 1.76 (s, 3 H, CH₃CO). Anal. Calcd for C₅₂H₄₈O₁₆: C, 67.27; H, 5.21. Found: C, 67.37; H, 5.31.

3.10. Methyl 2,3,4,6-tetra-*O*-benzoyl-β-D-glucopyranosyl-(1 → 6)-2,4-di-*O*-acetyl-3-*O*-allyl-β-D-glucopyranosyl-(1 → 2)-4,6-*O*-benzylidene-α-D-glucopyranoside (16)

2,3,4,6-Tetra-*O*-benzoyl-β-D-glucopyranosyl-(1 → 6)-2,4-di-*O*-acetyl-3-*O*-allyl-α-D-glucopyranosyl trichloroacetimidate (**15**, 100 mg, 0.1 mmol) and methyl 4,6-*O*-benzylidene-α-D-glucopyranoside (**2**, 30 mg, 0.11 mmol) were dried together under high vacuum for 2 h, then dissolved in anhyd CH₂Cl₂ (5 mL). TMSOTf (8 μL) was added dropwise at –20 °C with N₂ protection. The reaction mixture was stirred for 3 h, during which time the temperature was gradually raised to ambient temperature. Then the mixture was neutralized with Et₃N. Concentration of the reaction mixture, followed by purification on a silica gel column with 2:1 petroleum ether–EtOAc as the eluent, gave the trisaccharide (72 mg, 63%). The trisaccharide was acetylated in pyridine (2 mL) with Ac₂O (0.5 mL), then concentrated to dryness. The residue was purified by flash chromatography (2:1 petroleum ether–EtOAc) to give the 3-acetate of **16** (70 mg, 94%) as a syrup: $[\alpha]_D + 12.0^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.06–7.25 (m, 25 H, PhH), 5.88 (dd, 1 H, $J_{3'',4''} = J_{4'',5''} = 9.6$ Hz, H-4''), 5.72–5.68 (m, 1 H, –CH=), 5.68 (dd, 1 H, $J_{3'',4''} = J_{2'',3''} = 9.6$ Hz, H-3''), 5.57–5.47 (m, 3 H, H-2'', H-3, PhCH), 5.22–5.15 (m, 2 H, CH₂=), 5.01 (d, 1 H, $J_{1'',2''}$ 8.0 Hz, H-1''), 4.86 (dd, 1 H, $J_{4',5'} = J_{4',3'} = 9.6$ Hz, H-4'), 4.80 (d, 1 H, $J_{1,2}$ 4.0 Hz, H-1), 4.78 (dd, 1 H, $J_{2',3'}$ 9.6, $J_{1',2'}$ 8.0 Hz, H-2'), 4.65–4.48 (m, 2 H), 4.45 (dd, 1 H $J_{1',2'}$ 8.0 Hz, H-1'), 4.30–4.12 (m, 2 H), 3.96–3.75 (m, 4 H), 3.71 (dd, 1 H, $J_{2,3}$ 9.6, $J_{1,2}$ 4.0 Hz, H-2), 3.67 (dd, 1 H, $J_{3,4} = J_{4,5} = 9.6$ Hz, H-4), 3.65–3.63 (m, 1 H), 3.43 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 3.36 (s, 3 H, CH₃O), 2.09 (s, 3 H, CH₃CO), 2.07 (s, 3 H, CH₃CO), 1.99 (s, 3 H, CH₃CO). Anal. Calcd for C₆₃H₆₄O₂₃: C, 63.63; H, 5.42. Found: C, 64.01; H, 5.50.

3.11. Methyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 2)-4,6-*O*-benzylidene- α -D-glucopyranoside (**18**)

The 3-acetate of **18** (111 mg, 64% for two steps) was obtained as a syrup by coupling of 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- α -D-glucopyranosyl trichloroacetimidate (**17**, 150 mg, 0.15 mmol) with **2** (40 mg, 0.15 mmol) followed by acetylation under the same conditions as described for the preparation of the 3-acetate of **16**: $[\alpha]_D + 21.4^\circ$ (*c* 0.5, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.03–7.26 (m, 25 H, PhH), 5.90 (dd, 1 H, $J_{3'',4''} = J_{4'',5''} = 9.6$ Hz, H-4''), 5.68 (dd, 1 H, $J_{3'',4''} = J_{2'',3''} = 9.6$ Hz, H-3''), 5.43 (s, 1 H, PhCH), 5.43–5.38 (m, 2 H, H-4', H-2''), 5.03 (dd, 1 H, $J_{3,4} = J_{2,3} = 9.6$ Hz, H-3), 4.92 (dd, 1 H, $J_{1',2'} = 8.0$, $J_{2',3'} = 9.6$ Hz, H-2'), 4.89 (d, 1 H, $J_{1'',2''} = 8.0$ Hz, H-1''), 4.74 (d, 1 H, $J_{1,2} = 3.6$ Hz, H-1), 4.61–4.50 (m, 2 H), 4.47 (d, 1 H, $J_{1',2'} = 8.0$ Hz, H-1'), 4.38–4.07 (m, 4 H), 3.97–3.69 (m, 3 H), 3.62 (dd, 1 H, $J_{1,2} = 4.0$, $J_{2,3} = 9.6$ Hz, H-2), 3.54–3.46 (m, 2 H), 3.32 (s, 3 H, CH₃O), 2.08, 2.06, 1.97, 1.90 (4 s, 12 H, 4 CH₃CO). Anal. Calcd for C₆₂H₆₂O₂₄: C, 62.52; H, 5.25. Found: C, 62.27; H, 5.31.

3.12. Allyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 2)-4,6-*O*-benzylidene- α -D-glucopyranoside (**19**)

The 3-acetate of **19** (105 mg, 59% for two steps) was obtained as a syrup by coupling of **17** (150 mg, 0.15 mmol) with **5** (45 mg, 0.15 mmol), followed by acetylation under the same conditions as described for the preparation of the 3-acetate of **16**: $[\alpha]_D + 8.2^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.04–7.29 (m, 25 H, PhH), 5.92 (dd, 1 H, $J_{3'',4''} = J_{4'',5''} = 9.6$ Hz, H-4''), 5.85 (m, 1 H, –CH=), 5.70 (dd, 1 H, $J_{3'',4''} = J_{2'',3''} = 9.6$ Hz, H-3''), 5.44 (s, 1 H, PhCH), 5.43 (dd, 1 H, $J_{1'',2''} = 8.0$, $J_{2'',3''} = 9.6$ Hz, H-2''), 5.32–5.15 (m, 2 H, CH₂=), 5.04 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.02 (d, 1 H, $J_{1',2'} = 4.0$ Hz, H-1''), 4.95–4.90 (m, 3 H, H-2', H-3, H-1), 4.65–4.54 (m, 2 H), 4.50 (d, 1 H, $J_{1,2} = 8.0$ Hz, H-1'), 4.30–3.95 (m, 7 H), 3.72–3.69 (m, 1 H), 3.66 (dd, 1 H, $J_{1,2} = 4.0$, $J_{2,3} = 9.6$ Hz, H-2), 3.59–3.50 (m, 2 H), 2.09, 2.09, 1.99, 1.91 (3 s, 12 H, 4 CH₃CO). Anal. Calcd for C₆₄H₆₄O₂₄: C, 63.15; H, 5.30. Found: C, 63.35; H, 5.30.

3.13. Methyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 2)-4,6-*O*-benzylidene- β -D-glucopyranoside (**20**)

The 3-acetate of **20** (121 mg, 70% for two steps) was prepared as a syrup by coupling of **17** (150 mg, 0.15 mmol) with **9** (40 mg, 0.15 mmol), followed by acetylation under the same conditions as described for the preparation of the 3-acetate of **16**: $[\alpha]_D - 15.3^\circ$ (*c* 1.0,

CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.02–7.26 (m, 25 H, PhH), 5.90 (dd, 1 H, $J_{3'',4''} = J_{4'',5''} = 9.6$ Hz, H-4''), 5.65 (dd, 1 H, $J_{3'',4''} = J_{2'',3''} = 9.6$ Hz, H-3''), 5.44 (s, 1 H, PhCH), 5.42 (dd, 1 H, $J_{1'',2''} = 8.0$, $J_{2'',3''} = 9.6$ Hz, H-2''), 5.09 (dd, 1 H, $J_{3',4'} = J_{4',5'} = 9.6$ Hz, H-4'), 5.00 (dd, $J_{1',2'} = 8.0$, $J_{2',3'} = 9.6$ Hz, H-2'), 4.98 (d, 1 H, $J_{1'',2''} = 8.0$ Hz, H-1''), 4.89 (dd, 1 H, $J_{3,4} = J_{2,3} = 9.6$ Hz, H-3), 4.70 (d, 1 H, $J_{1',2'} = 8.0$ Hz, H-1'), 4.67–4.50 (m, 2 H), 4.34 (d, 1 H, $J_{1,2} = 3.2$ Hz, H-1), 4.33–4.29 (m, 1 H), 4.28–4.11 (m, 2 H), 3.93–3.91 (m, 1 H), 3.68–3.66 (m, 1 H), 3.64 (dd, $J_{1,2} = 8.0$, $J_{2,3} = 9.6$ Hz, H-2), 3.64–3.62 (m, 1 H), 3.59–3.54 (m, 1 H), 3.47 (s, 3 H, CH₃O), 3.41–3.34 (m, 1 H), 2.06, 2.04, 1.96, 1.95 (4 s, 12 H, 4 CH₃CO). Anal. Calcd for C₆₂H₆₂O₂₄: C, 62.52; H, 5.25. Found: C, 62.48; H, 5.41.

3.14. Allyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-2,4,6-tri-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 2)-4,6-*O*-benzylidene- β -D-glucopyranoside (**21**)

The 3-acetate of **21** (105 mg, 59% for two steps) was obtained as a syrup by coupling of **17** (150 mg, 0.15 mmol) with **12** (45 mg, 0.15 mmol), followed by acetylation under the same conditions as described for the preparation of the 3-acetate of **16**: $[\alpha]_D - 25.5^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 7.95–7.18 (m, 25 H, PhH), 5.82 (dd, 1 H, $J_{3'',4''} = J_{4'',5''} = 9.6$ Hz, H-4''), 5.80 (m, 1 H, –CH=), 5.60 (dd, 1 H, $J_{3'',4''} = J_{2'',3''} = 9.6$ Hz, H-3''), 5.36 (s, 1 H, PhCH), 5.34 (dd, 1 H, $J_{1'',2''} = 8.0$, $J_{2'',3''} = 9.6$ Hz, H-2''), 5.25–5.07 (m, 2 H, CH₂=), 5.02–4.98 (m, 2 H, H-4' H-3), 4.87 (d, 1 H, $J_{1'',2''} = 8.0$ Hz, H-1''), 4.83 (dd, 1 H, $J_{1',2'} = 8.0$, $J_{2',3'} = 9.2$ Hz, H-2'), 4.61 (d, 1 H, $J_{1',2'} = 8.0$ Hz, H-1'), 4.56–4.46 (m, 2 H), 4.43 (d, 1 H, $J_{1,2} = 8.0$ Hz, H-1), 4.24–4.20 (m, 2 H), 4.08–4.01 (m, 4 H), 3.85 (dd, 1 H, $J_{3',4'} = J_{2',3'} = 9.6$ Hz, H-3'), 3.64–3.59 (m, 2 H), 3.58 (dd, 1 H, $J_{1,2} = 8.0$, $J_{2,3} = 9.6$ Hz, H-2), 3.51–3.45 (m, 1 H), 3.38–3.29 (m, 1 H), 2.00, 1.98, 1.88, 1.86 (4 s, 12 H, 4 CH₃CO). Anal. Calcd for C₆₄H₆₄O₂₄: C, 63.15; H, 5.30. Found: C, 63.31; H, 5.17.

3.15. Allyl 2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 3)-[2,3,4,6-tetra-*O*-benzoyl- β -D-glucopyranosyl-(1 \rightarrow 6)]-2,4-di-*O*-acetyl- β -D-glucopyranosyl-(1 \rightarrow 2)-4,6-*O*-benzylidene- α -D-glucopyranoside (**23**)

The 3-acetate of **23** (135 mg, 53% for two steps) was obtained as a syrup by coupling of **22** (235 mg, 0.15 mmol) with **5** (45 mg, 0.15 mmol), followed by acetylation under the same conditions as described for the preparation of the 3-acetate of **16**: $[\alpha]_D + 21.3^\circ$ (*c* 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ 8.01–7.32 (m, 45 H, 9 PhH), 5.88 (t, 1 H, $J = 9.6$ Hz), 5.86 (t, 1 H, $J = 9.6$ Hz), 5.82–5.75 (m, 1 H, –CH=), 5.68–5.6 (m, 2 H), 5.49 (s, 1 H, PhCH), 5.48–5.45 (m, 2 H), 5.37 (t, 1 H, $J = 9.6$ Hz), 5.22–5.02 (m, 2 H), 5.01 (d, 1 H, $J = 8.0$ Hz,

H-1), 4.88 (d, 1 H, J 3.6 Hz, H-1), 4.84 (d, 1 H, J 7.6 Hz, H-1), 4.79–4.70 (m, 2 H), 4.66–4.56 (m, 2 H), 4.49–4.44 (m, 2 H), 4.37 (d, 1 H, J 8.0 Hz, H-1), 4.18–4.09 (m, 3 H), 4.04–3.98 (m, 1 H), 3.94–3.88 (m, 2 H), 3.85–3.72 (m, 4 H), 3.68 (dd, 1 H, $J_{1,2}$ 2.8, $J_{2,3}$ 10.4 Hz, H-2), 3.62–3.54 (m, 2 H), 2.04, 1.90, 1.85 (3 s, 9 H, CH_3CO). Anal. Calcd for $\text{C}_{96}\text{H}_{88}\text{O}_{32}$: C, 65.75; H, 5.06. Found: C, 66.05; H, 4.98.

Acknowledgements

This work was supported by The Chinese Academy of Sciences (KZCX3-J-08) and by The National Natural Science Foundation of China (Projects 39970864 and 30070815).

References

- (a) ; Khan, S. H.; O'Neil, R. A., Eds. *Modern Methods in Carbohydrate Synthesis*; Harwood Academic Publishers: United States, 1996; pp 125–150;
(b) Seeberger, P. H.; Eckhardt, M.; Utteridge, C. E.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1997**, *119*, 10064–10070.
- (a) Wang, W.; Kong, F. *J. Org. Chem.* **1998**, *63*, 5744–5745;
(b) Wang, W.; Kong, F. *Angew. Chem., Int. Ed. Engl.* **1999**, *38*, 1247–1250;
(c) Zhu, Y.; Kong, F. *Synlett* **2001**, 1217–1220;
(d) Zhang, J.; Kong, F. *Tetrahedron: Asymmetry* **2002**, *13*, 243–252;
(e) Ning, J.; Yi, Y.; Kong, F. *Tetrahedron Lett.* **2002**, *43*, 5545–5549.
- (a) Sasaki, T.; Takasuka, N. *Carbohydr. Res.* **1976**, *47*, 99–110;
(b) Kitamura, S.; Hori, T.; Kurita, K.; Takeo, K.; Hara, C.; Itoh, W.; Tabata, K.; Elgsaeter, A.; Stokke, B. T. *Carbohydr. Res.* **1994**, *263*, 111–120;
(c) Chihara, G.; Maeda, Y.; Hamuro, J.; Sasaki, T.; Fukuoka, F. *Nature* **1969**, *222*, 687–690;
(d) Schmid, F.; Stone, B. A.; McDougall, B. M.; Basic, A.; Martin, K. L.; Brownlee, R. T. C.; Chai, E.; Seviour, R. J. *Carbohydr. Res.* **2001**, *331*, 163–171.
- (a) Adeyeye, A.; Jansson, P. E.; Lindberg, B. *Carbohydr. Res.* **1988**, *180*, 295–299;
(b) Tokuyasu, K.; Ono, H.; Ohnishi-Kameyama, M.; Hayashi, K.; Mori, Y. *Carbohydr. Res.* **1997**, *303*, 453–458.
- (a) Muddasani, P. R.; Bernet, B.; Vasella, A. *Helv. Chim. Acta* **1994**, *77*, 257–290;
(b) Muddasani, P. R.; Bozo, E.; Bernet, B.; Vasella, A. *Helv. Chim. Acta* **1994**, *77*, 334–350.
- (a) Fraser-Reid, B.; Lopez, J. C.; Radhakrishnan, K. V.; Mach, M.; Schlueter, U.; Gomez, A. M.; Uriel, C. *J. Am. Chem. Soc.* **2002**, *124*, 3198–3199;
(b) Anilkumar, G.; Jia, Z. J.; Kraehmer, R.; Fraser-Reid, B. *J. Chem. Soc., Perkin Trans. 1* **1999**, 3591–3596;
(c) Anilkumar, G.; Nair, L. G.; Fraser-Reid, B. *Org. Lett.* **2000**, *2*, 2587–2589.